Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This piece marks the tenth anniversary of the American Board of Hair Restoration Surgery and highlights the addition of 14 new diplomates from diverse countries, while reporting no new clinical findings.

This article summarizes a meeting of the American Board of Hair Restoration Surgery's Board of Directors to discuss future plans, but does not report new experimental results.

In this study, CD4+ non-haematopoietic, skin-resident stem cell-like populations were identified in both murine and human epidermis, suggesting they may serve as potential basal cell carcinoma precursors.

This source describes the American Board of Hair Restoration Surgery's mission to set standards and evaluate skills in hair restoration surgery, but does not report any specific study results.

CaBP1 and 2 are necessary for maintaining calcium currents and hearing in inner ear cells.

This study identified a new gene, mrp4, in mice, which suggests it may have a unique role in the growth and development of hair follicles in the ears and tails.

This research suggests that the barley protein RACB supports cell polarity functions rather than interfering with immunity, as it aids nucleus positioning during fungal attack rather than affecting early immune responses.

This abstract provides information about the American Board of Hair Restoration Surgery as the only internationally accepted certifying body for hair restoration surgeons, but it reports no new research results.

This announcement from the American Board of Hair Restoration Surgery details the establishment of two oral examinations for 2024, with the first taking place at the Italian/European Congress in Milan, Italy, in May.

This study found a severe MBTPS2 gene mutation in a Japanese IFAP syndrome patient, suggesting other factors may influence the syndrome's clinical features compared to previously studied patients.

This review discusses the latest findings presented at the 4th Intercontinental Meeting of Hair Research Societies, covering advances in hair follicle biology, genetic bases for hair disorders, and potential new therapeutic approaches, but it reports no original study results.

This study found significantly higher levels of Toll-Like Receptor 4, interferon gamma, and interleukin-17 in Iraqi patients with alopecia areata compared to controls, suggesting these immune markers play a crucial role in the disease's development and could be targets for future treatments.

In laboratory experiments, this study found that the topical prodrug SCD-153, a derivative of 4-methyl itaconate, reduced inflammation-related gene expression and induced significant hair growth in mice, suggesting it as a promising treatment candidate for alopecia areata.

In this study, patients with severe alopecia areata treated with baricitinib showed continued improvement in scalp hair regrowth from weeks 52 to 152, particularly among those initially responding with eyelash or eyebrow regrowth but not scalp hair, with 39% achieving substantial regrowth by week 104.

This phase 3 trial found that over 50% of adolescents with severe alopecia areata achieved successful hair regrowth after 52 weeks on baricitinib 4-mg, with no new safety concerns reported compared to existing safety profiles.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

This study suggests that thymosin beta 4 may regulate hair growth by influencing VEGF and MMP-2 levels through the Wnt/β-catenin/Lef-1 signaling pathway in mouse models.

This study found that altering cyclin-dependent kinase 4 (CDK4) levels in the bulge region of hair follicles affects the balance of stem cell numbers, potentially influencing hair follicle self-renewal and proliferation.

This study found that inhibiting DPP4 during a critical period post-wounding increases hair follicle regeneration and Wnt signaling in large skin wounds.

This study assessed patient satisfaction and hair retention in 15 individuals with alopecia treated with Biofibre ® 4.0 artificial hair implants, finding high levels of satisfaction and excellent biocompatibility, with no significant adverse reactions reported after one year.

This study investigated autophagy activator ICP5249 and found it promotes hair growth by enhancing cell proliferation and autophagy-related markers in human dermal papilla cells and hair follicles, with AMPKα playing a regulatory role, suggesting its potential as a hair growth ingredient.

This study describes the patterns of clinical response in patients with severe alopecia areata treated with baricitinib over 52 weeks, based on integrated data from two Phase 3 trials.

In this study, a strong positive correlation was found between clinician-reported and patient-reported measures for assessing eyebrow and eyelash hair loss in patients with severe alopecia areata, indicating high agreement during treatment with baricitinib over 52 weeks.

This study found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg for treating severe alopecia areata at Weeks 24 and 52, potentially influencing reimbursement decisions.

Baricitinib reduces inflammation and mitochondrial damage in skin cells.

In this phase 2a study of adults with alopecia areata, researchers observed that ritlecitinib treatment did not result in significant differences in brainstem auditory evoked potential changes or axonal swelling compared to placebo, suggesting the dog toxicity findings may not be clinically relevant in humans.

In this study, baricitinib treatment for severe alopecia areata was well tolerated, with minor metabolic changes and PLR emerging as a sensitive marker of treatment response.

This study found that patients with rheumatoid arthritis, atopic dermatitis, and alopecia areata receiving baricitinib had low incidence rates of adverse events, especially among low-risk individuals, with varying rates among those at higher risk.

In in-vitro experiments, this study found that poncirin showed higher inhibitory activity against JAK3 than tofacitinib, suggesting potential for alopecia areata treatment.

In this retrospective study, researchers found that baricitinib was effective for treating moderate to severe alopecia areata, with response rates in 24 patients comparable to existing real-world data, and no new safety concerns were identified.